A new executive order from President Trump instructs federal agencies to develop recommendations within 180 days for improving Medicaid drug rebate accuracy, advancing value-based payment arrangements for pharmaceuticals, and supporting state-level strategies to manage drug spending. While much of the order focuses on Medicare reforms—including changes to IRA negotiation guidance and new CMMI pricing models—the Medicaid provisions signal potential federal action that could reshape how MCOs and states approach pharmacy benefit design and financial management. The directive suggests increased federal attention to pharmacy cost containment as a priority area for Medicaid managed care plans.

Federal proposals to prohibit PBMs from earning compensation tied to drug prices or manufacturer rebates—requiring instead flat service fees—could fundamentally change how Medicaid managed care plans contract for pharmacy benefit management. While delinking bills have focused primarily on Medicare Part D and commercial markets, the policy shift would affect PBM operations across all lines of business including Medicaid, potentially altering incentive structures that currently encourage deeper manufacturer discounts. MCOs would need to evaluate how mandatory flat-fee arrangements impact their ability to maximize drug rebates and manage pharmacy costs under capitated payment models.

Manatt Health released a state-by-state analysis tool estimating how proposed Congressional cuts—including reduced federal matching rates for expansion adults, elimination of the 50% FMAP floor, and per-capita caps—would affect Medicaid spending and enrollment through 2034. The toolkit models scenarios ranging from states ending expansion (resulting in a 32% national enrollment drop) to states backfilling lost federal funds (requiring $836 billion in new state spending). This resource gives state Medicaid directors and MCO executives concrete data to inform budget planning and advocacy as reconciliation proposals advance.

The 2024 Older Americans Act Final Rule—the first major regulatory update in decades—requires Area Agencies on Aging to modernize operations and improve business efficiency as they deliver community-based long-term services and supports. For Medicaid managed care plans, stronger AAA performance means better coordination on home and community-based services that can delay or prevent costly institutional care for dual-eligible and LTSS populations. States are now linking AAA network investments to measurable outcomes as part of broader Master Plans on Aging.

This piece argues that technology innovations—particularly predictive analytics, AI-driven risk stratification, and telehealth expansion—offer critical pathways for Medicaid programs to improve care coordination, address social determinants of health, and reach underserved populations more effectively. It emphasizes how data integration between MCOs, state agencies, and providers can reduce administrative burden while enabling proactive interventions for high-risk enrollees. The analysis is directly relevant to MCO compliance teams implementing these technologies and state Medicaid directors setting policy frameworks for their adoption.

The Trump administration's executive order to close the Department of Education raises questions about federal oversight of special education services for over 7.5 million children with intellectual and developmental disabilities, including enforcement of IDEA requirements and distribution of funding. The analysis highlights potential implications for Medicaid managed care organizations, as many early intervention programs coordinate closely with state Medicaid programs, and changes to federal education policy could affect how MCOs deliver coordinated care to children with disabilities. The restructuring could shift compliance responsibilities and funding mechanisms that currently support integrated service delivery between education and health systems.

California, Oregon, and Washington have introduced legislation tightening corporate practice of medicine prohibitions, which could force restructuring of private equity-backed management service organizations and physician practice arrangements. The bills would restrict MSO control over clinical decisions, impose stricter physician ownership requirements, and limit certain contractual arrangements between professional corporations and management companies. These changes could affect how Medicaid managed care plans contract with provider groups that rely on private equity backing or MSO structures, potentially impacting network adequacy and provider availability.

California has evolved its approach to nutrition interventions within Medi-Cal managed care, moving from its 2022 launch of medically tailored meals as an optional "in lieu of services" Community Support to increasingly standardized offerings based on stakeholder feedback. The state's experience illustrates how managed care plans are implementing social drivers of health benefits that aim to prevent costly downstream medical care for members with diet-sensitive conditions. This progression reflects broader Medicaid policy trends as CMS has formalized the in lieu of services authority that California pioneered for addressing social determinants through managed care.

Avalere projects that 18 million Americans receiving enhanced ACA marketplace premium tax credits will lose subsidies if they expire in 2025, including nearly 5 million adults ages 50–64. The analysis notes that marketplace enrollment surged partly due to Medicaid redeterminations following the end of the COVID-19 continuous coverage requirement, with approximately 4 million people ages 50–64 disenrolled from Medicaid between 2023 and 2024. The expiration could affect coverage pathways for populations that transitioned from Medicaid to marketplace plans during unwinding.

Milliman actuaries examine the structure of federal matching rates (FMAP) across traditional Medicaid, ACA expansion populations, CHIP, and administrative costs, analyzing how potential shifts in federal matching formulas could impact state Medicaid budgets. The white paper models three alternative scenarios for matching rate changes and their financial implications for state Medicaid programs. This analysis is directly relevant to state Medicaid directors and MCO finance teams navigating budget uncertainty and potential federal policy changes that affect managed care capitation funding.

Healthcare industry leaders predict accelerated movement toward full-risk contracting and capitation models in 2025, driven by efforts to reduce administrative burden that currently accounts for one-third of total healthcare spending. The discussion emphasizes that fundamental payment reform—not just technology—is necessary to improve care coordination and reduce costs. While the analysis covers broad healthcare trends rather than Medicaid-specific policy, the shift toward value-based arrangements and risk-based payment models has direct implications for Medicaid managed care operations and state contracting strategies.

Avalere surveyed health plan executives on Prescription Drug Affordability Boards (PDABs) and upper payment limits (UPLs) now authorized in four states. Plans anticipate UPLs will force changes to formularies, cost-sharing, and pharmacy reimbursement, with 80% identifying patients as most impacted and most expecting increased out-of-pocket costs despite state affordability goals. While focused on commercial and state policy broadly, the findings have direct implications for Medicaid managed care plans operating in states with PDAB authority, particularly around pharmacy benefits and network adequacy.

The Trump administration's early termination of the ESRD Treatment Choices model and ongoing transplant system reforms under the Increasing Organ Transplant Access model will affect how kidney care is delivered and paid for in 2025. These federal policy changes carry implications for Medicaid managed care organizations covering members with chronic kidney disease and end-stage renal disease, though the piece focuses primarily on Medicare policy with only indirect Medicaid relevance.

CMS published updated guidance in December 2024 on how states should develop and document Medicaid capitation rates for PACE organizations, which provide comprehensive care to elderly enrollees. The white paper explains changes to rate-setting methodology, including how to calculate the "Amount That Would Have Otherwise Been Paid" (AWOP) benchmark and broader implications for Medicaid capitation rate development. This matters for state Medicaid directors and actuaries responsible for setting compliant rates for PACE plans, as well as MCOs and health plans considering or operating PACE programs.

California's decade of child welfare reforms—including priority placement with families over institutions and expanded kinship care support—requires coordination across healthcare, education, and social services systems. For Medicaid managed care organizations, these shifts affect care for foster children and families receiving behavioral health services, though the piece focuses primarily on child welfare policy rather than Medicaid program specifics. The discussion of trauma-informed care, social determinants, and post-system support touches on areas where MCOs interface with child welfare agencies.

HHS has rescinded the Richardson Waiver, eliminating its longstanding commitment to seek public input before changing Medicaid policies. Because Medicaid is classified as a grant program under the Administrative Procedures Act, CMS may now adopt or revise managed care regulations without formal notice-and-comment periods unless other specific laws require it. This shift could significantly accelerate regulatory changes affecting MCOs and state Medicaid programs, though the extent to which CMS will use this authority remains unclear.

Healthcare providers serving children in foster care face significant challenges including incomplete medical records, behavioral health access barriers, and care disruptions from placement changes. The piece outlines specific strategies for MCOs and providers to leverage Medicaid EPSDT benefits, coordinate with child welfare agencies, and establish medical homes to address gaps—particularly critical given that 30% of foster children don't receive required screenings and 80% have mental health needs. It positions managed care organizations as key partners in creating specialized care models and reimbursement structures to support this vulnerable population.

A consulting firm helped Drexel University identify and access public funding mechanisms—likely including Medicaid supplemental payment programs and provider reimbursement strategies—to maintain operations at St. Christopher's Hospital for Children, a safety-net pediatric facility serving a medically underserved Philadelphia community. The case illustrates how Medicaid financing tools can be leveraged to sustain critical pediatric infrastructure serving vulnerable populations, though the piece is primarily a client testimonial rather than substantive policy analysis.

This white paper provides Medicaid managed care plans with a framework for optimizing care coordination for enrollees with sickle cell disease, addressing specialized service access, continuity of care, and patient education. It examines how technology can reduce avoidable costs and improve care coordination, and explores integrating federal disease action plans and health equity frameworks to reduce acute care utilization. The analysis is particularly timely given new gene therapy approvals that may reshape treatment approaches for this Medicaid population.

The piece examines how 2024's strengthened mental health parity enforcement and emerging psychedelic treatments are creating new compliance pressures and potential coverage expansion obligations for health plans. While it addresses behavioral health policy changes affecting payer compliance and benefit design, the analysis does not specifically focus on Medicaid managed care or distinguish Medicaid implications from commercial and employer-sponsored coverage. The relevance to Medicaid MCOs is real but indirect, as parity rules and treatment innovations affect all behavioral health payers.